Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jirí Wiesner

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Enzyme Inhibition and Medicinal Chemistry|September 13, 2007
Acetylcholinesterases--the structural similarities and differencesJirí Wiesner, Zdenek Kriz, Kamil Kuca, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|October 31, 2009
Why acetylcholinesterase reactivators do not work in butyrylcholinesteraseJirí Wiesner, Zdenek Kríz, Kamil Kuca, et al.
Cancer Research|November 19, 2004
The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxideMarie Stiborová, Jan Sejbal, Lucie Borek-Dohalská, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Enzyme Inhibition and Medicinal Chemistry|September 13, 2007
Acetylcholinesterases--the structural similarities and differencesJirí Wiesner, Zdenek Kriz, Kamil Kuca, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|October 31, 2009
Why acetylcholinesterase reactivators do not work in butyrylcholinesteraseJirí Wiesner, Zdenek Kríz, Kamil Kuca, et al.
Cancer Research|November 19, 2004
The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxideMarie Stiborová, Jan Sejbal, Lucie Borek-Dohalská, et al.
Pageof 1